WP
DAWN

Woodline Partners’s Day One Biopharmaceuticals DAWN Stock Holding History

Woodline Partners’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.05M Buy
+189,057
New +$2.66M 0.02% 698
2025
Q3 		– Sell
-100,516
Closed -$653K – 923
2025
Q2 		$653K Sell
100,516
-112,638
-53% -$775K ﹤0.01% 834
2025
Q1 		$1.69M Sell
213,154
-585,771
-73% -$6.31M 0.01% 690
2024
Q4 		$10.1M Buy
798,925
+1,592
+0.2% +$22.2K 0.07% 341
2024
Q3 		$11.1M Buy
797,333
+89,802
+13% +$1.28M 0.09% 277
2024
Q2 		$9.75M Buy
707,531
+434,993
+160% +$6.36M 0.09% 250
2024
Q1 		$4.5M Hold
272,538
– – 0.04% 371
2023
Q4 		$3.98M Hold
272,538
– – 0.04% 337
2023
Q3 		$3.34M Buy
272,538
+61,538
+29% +$803K 0.04% 352
2023
Q2 		$2.52M Buy
211,000
+59,972
+40% +$783K 0.03% 401
2023
Q1 		$2.02M Hold
151,028
– – 0.03% 422
2022
Q4 		$3.25M Buy
+151,028
New +$3.1M 0.04% 385
2022
Q3 		– Sell
-150,176
Closed -$2.69M – 770
2022
Q2 		$2.69M Buy
+150,176
New +$1.55M 0.04% 386

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Woodline Partners's DAWN Position: Q1 2026 in Review

Woodline Partners opened a new position in Day One Biopharmaceuticals (DAWN) in Q1 2026: 189,057 shares worth $4.05M. The stake represents 0.02% of the portfolio and ranks #698 among its holdings. This is a return to the name: Woodline Partners previously reported a position in DAWN as recently as Q2 2025.

Woodline Partners first reported a position in DAWN in Q2 2022 and has held it in 13 quarters since. The position peaked at $11.1M in Q3 2024. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Woodline Partners held 189,057 shares of Day One Biopharmaceuticals worth $4.05M as of Q1 2026.
  • Day One Biopharmaceuticals was a new Woodline Partners position in Q1 2026.
  • Day One Biopharmaceuticals made up 0.02% of Woodline Partners's portfolio in Q1 2026, its #698 holding.
  • Woodline Partners first reported a position in Day One Biopharmaceuticals in Q2 2022 and has held it in 13 quarters since.
  • Woodline Partners's Day One Biopharmaceuticals position peaked at $11.1M in Q3 2024.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.